Oppenheimer Sticks to Its Buy Rating for Frequency Therapeutics (FREQ)

Oppenheimer analyst Jay Olson maintained a Buy rating on Frequency Therapeutics (FREQResearch Report) today and set a price target of $20.00. The company’s shares closed last Wednesday at $9.43, close to its 52-week low of $7.34.

According to TipRanks.com, Olson is a 2-star analyst with an average return of 0.4% and a 42.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Enanta Pharmaceuticals.

Frequency Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.00, representing a 334.8% upside. In a report issued on March 23, B.Riley Financial also maintained a Buy rating on the stock with a $35.00 price target.

See today’s analyst top recommended stocks >>

Frequency Therapeutics’ market cap is currently $287.1M and has a P/E ratio of -3.50. The company has a Price to Book ratio of 1.38.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FREQ in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean in November 13, 2014 and is headquartered in Woburn, MA.